|
Gene: HINT3 |
Gene summary for HINT3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HINT3 | Gene ID | 135114 |
Gene name | histidine triad nucleotide binding protein 3 | |
Gene Alias | HINT4 | |
Cytomap | 6q22.32 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NQE9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
135114 | HINT3 | LZE4T | Human | Esophagus | ESCC | 5.03e-12 | 2.00e-01 | 0.0811 |
135114 | HINT3 | LZE7T | Human | Esophagus | ESCC | 7.94e-04 | 1.75e-01 | 0.0667 |
135114 | HINT3 | LZE24T | Human | Esophagus | ESCC | 2.62e-14 | 3.59e-01 | 0.0596 |
135114 | HINT3 | P1T-E | Human | Esophagus | ESCC | 1.07e-03 | 2.39e-01 | 0.0875 |
135114 | HINT3 | P2T-E | Human | Esophagus | ESCC | 3.49e-20 | 4.54e-01 | 0.1177 |
135114 | HINT3 | P4T-E | Human | Esophagus | ESCC | 6.00e-16 | 4.66e-01 | 0.1323 |
135114 | HINT3 | P5T-E | Human | Esophagus | ESCC | 1.87e-10 | 2.45e-01 | 0.1327 |
135114 | HINT3 | P8T-E | Human | Esophagus | ESCC | 3.92e-13 | 2.36e-01 | 0.0889 |
135114 | HINT3 | P9T-E | Human | Esophagus | ESCC | 5.26e-05 | 4.72e-02 | 0.1131 |
135114 | HINT3 | P10T-E | Human | Esophagus | ESCC | 2.45e-12 | 1.38e-01 | 0.116 |
135114 | HINT3 | P11T-E | Human | Esophagus | ESCC | 8.35e-06 | 1.43e-01 | 0.1426 |
135114 | HINT3 | P12T-E | Human | Esophagus | ESCC | 2.25e-23 | 4.00e-01 | 0.1122 |
135114 | HINT3 | P15T-E | Human | Esophagus | ESCC | 6.10e-19 | 4.95e-01 | 0.1149 |
135114 | HINT3 | P16T-E | Human | Esophagus | ESCC | 1.99e-17 | 2.88e-01 | 0.1153 |
135114 | HINT3 | P17T-E | Human | Esophagus | ESCC | 1.02e-07 | 1.91e-01 | 0.1278 |
135114 | HINT3 | P19T-E | Human | Esophagus | ESCC | 1.78e-07 | 4.37e-01 | 0.1662 |
135114 | HINT3 | P20T-E | Human | Esophagus | ESCC | 5.15e-07 | 6.29e-02 | 0.1124 |
135114 | HINT3 | P21T-E | Human | Esophagus | ESCC | 5.67e-15 | 2.32e-01 | 0.1617 |
135114 | HINT3 | P22T-E | Human | Esophagus | ESCC | 6.38e-13 | 9.73e-02 | 0.1236 |
135114 | HINT3 | P23T-E | Human | Esophagus | ESCC | 2.08e-11 | 3.71e-01 | 0.108 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HINT3 | SNV | Missense_Mutation | c.208N>A | p.Asp70Asn | p.D70N | Q9NQE9 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
HINT3 | SNV | Missense_Mutation | novel | c.226N>T | p.Asp76Tyr | p.D76Y | Q9NQE9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
HINT3 | SNV | Missense_Mutation | novel | c.226N>T | p.Asp76Tyr | p.D76Y | Q9NQE9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
HINT3 | SNV | Missense_Mutation | c.137N>T | p.Ser46Ile | p.S46I | Q9NQE9 | protein_coding | tolerated(0.05) | benign(0.231) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
HINT3 | SNV | Missense_Mutation | c.284A>G | p.Asn95Ser | p.N95S | Q9NQE9 | protein_coding | tolerated(0.14) | benign(0.31) | TCGA-A5-A0GN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HINT3 | SNV | Missense_Mutation | c.359G>T | p.Arg120Ile | p.R120I | Q9NQE9 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HINT3 | SNV | Missense_Mutation | novel | c.536N>T | p.Lys179Ile | p.K179I | Q9NQE9 | protein_coding | deleterious(0.01) | benign(0.031) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HINT3 | SNV | Missense_Mutation | c.359G>T | p.Arg120Ile | p.R120I | Q9NQE9 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HINT3 | SNV | Missense_Mutation | novel | c.91N>G | p.Thr31Ala | p.T31A | Q9NQE9 | protein_coding | tolerated(0.12) | benign(0.039) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
HINT3 | SNV | Missense_Mutation | c.359N>T | p.Arg120Ile | p.R120I | Q9NQE9 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |